A new class of potent RAR antagonists: Dihydroanthracenyl, benzochromenyl and benzothiochromenyl retinoids

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 5, 1999, Pages 743-748

  Vuligonda, Vidyasagar ^a   Standeven, Andrew M ^a   Escobar, Maria ^a   Chandraratna, Roshantha A S ^a  

^a ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [5,6 DIHYDRO 5,5 DIMETHYL 8 (4 METHYLPHENYL) 2 NAPHTHYL]ETHYNYL]BENZOIC ACID; 4 CHROMANONE DERIVATIVE; ALITRETINOIN; ANTHRACENE DERIVATIVE; CHROMENE DERIVATIVE; N,N DIMETHYLFORMAMIDE; NAPHTHALENE DERIVATIVE; NEW DRUG; RECEPTOR BLOCKING AGENT; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ANTAGONIST; RETINOID X RECEPTOR; THIOCHROMAN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CHEMICAL REACTION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; NONHUMAN; NUDE MOUSE; SKIN TOXICITY; TOPICAL DRUG ADMINISTRATION;

ANIMALS; ANTHRACENES; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; HUMANS; RECEPTORS, RETINOIC ACID; RETINOIDS; TRANS-ACTIVATION (GENETICS); TRANSFECTION;

ANIMALIA; MUS MUSCULUS;

EID: 0033535414     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00077-3     Document Type: Article

References (38)

1. nd Ed.; Sporn, M. B.; Goodman, D. S. Eds.; Raven: New York, 1994; pp 319-349.
2. (a) Petkovich, M.; Brand, N. J.; Krust, A.; Chambon, P. Nature 1987, 330, 444.
3. (b) Giguere, V.; Ong, E. S.; Segui, P.; Evans, R. M. Nature 1987, 330, 624.
4. c) Brand, N.; Petkovich, M.; Krust, A.; Chambon, P.; Dethe, H.; Marchio, A.; Dejean, A. Nature 1988, 332, 850.
5. (d) Krust, A.; Kastner, P.; Petkovich, M.; Zelent, A.; Chambon, P. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 5310.
6. Mangelsdorf, D. J.; Borgmeyer, U.; Heyman, R. A.; Zhou, Y. U.; Ong, E. S.; Oro, A. E.; Kakizuka, A.; Evans, R. M. Genes Dev. 1992, 6, 329.
7. (a) Heyman, R. A.; Mangelsdorf, D. J.; Dyck, J. A.; Stein, R. B.; Eichele, G.; Evans, R. M.; Thaller, C. Cell 1992, 68, 397.
8. (b) Levin, A. A.; Sturzenbecker, L. J.; Kazmer, S.; Bosakowski, T.; Huselton, C.; Allenby, G.; Speck, J.; Kratzeisen, C. I.; Rosenberger, M.; Lovey, A.; Grippo, J. F. Nature 1992, 355, 359.
9. (a) Yu, V. C.; Delsert, C.; Andersen, B.; Holloway, J. M.; Devary, O. V.; Naar, A. M.; Kim, S.Y.; Boutin, J. M.; Glass, C. K.; Rosenfeld, M. G. Cell 1991, 67, 1251.
10. (b) Zhang, X.-K.; Hoffman, B.; Tran, P. B.-V.; Graupner, G.; Pfahl, M. Nature 1992, 355, 441.
11. (c) Leid, M.; Kastner, P.; Lyons, R.; Nakshari, H.; Saunders, M.; Zacharewski, T.; Chen, J. Y.; Staub, A.; Garnier, J. M.; Mader, S.; Chambon, P. Cell 1992, 68, 377.
12. (d) Kleiwer, S. A.; Umesono, K.; Mangelsdorf, D. J.; Evans, R. M. Nature 1992, 355, 446.
13. (e) Bugge, T. H.; Pohl, J.; Lonnoy, H. G.; Stunnenburg, H. G. EMBO J. 1992, 11, 1409.
14. (f) Marks, M. S.; Hallenbrook, P. L.; Nagata, T.; Segars, J. H.; Appela, E.; Nikodem, V. M.; Ozato, K. EMBO J. 1992, 11, 1419.
15. nd Ed.; Sporn, M. B. Roberts, A. B. Goodman, D. S. Eds.; Raven: New York, 1994.
16. (a) Nagpal, S.; Chandraratna, R. A. S.; Annual Reports in Medicinal Chemistry-32 1997, 201.
17. (b) Nagpal, S.; Chandraratna, R. A. S. Cur. Pharm. Design. 1996, 2, 295.
18. (c) Boehm, M. F.; Heyman, R. A.; Patel, S.; Stein, R. B.; Nagpal, S.; Exp. Opin. Invest. Drugs. 1995, 4, 593.
19. The Pharmacological Basis of Therapeutics Hardman, J. G.; Limbird, L. E.; Molinoff, P. B.; Ruddon, R. W.; Gilman, A. G., Eds. McGraw Hill, New York, 1996: pp1361-1546.
20. (a) Kaneko, S.; Kagechiko, H.; Kawachi, E.; Hashimoto, Y.; Shudo, K. Med. Chem. Res. 1991, 1, 220.
21. (b) Eyrolles, L.; Kagechiko, H.; Kawachi, E.; Fukasawa, H.; Iijama. T.; Matsushima, Y.; Hashimoto, Y.; Shudo, K. J. Med. Chem. 1994, 37, 1508.
22. (c) Yoshimura, H.; Nagai, M.; Hibi, S.; Kikuchi, K.; Abe, S.; Hida, T.; Higashi, S.; Hishinuma, I.; Yamanaka, T. J. Med. Chem. 1995, 38, 3163.
23. (d) Fanjun, A.; Dawson, M. I.; Hobbs, P. D.; Jong, L.; Cameron, J. F.; Narlev, E.; Graupner, G.; Lu, X-P.; Pfahl, M. Nature 1994, 372, 107.
24. (e) Chen, J.-Y.; Penco, S.; Ostrowski, J.; Balaguer, P.; Pons, M.; Starrett, J. E. Jr.; Reczek, P.; Chambon, P.; Gronemeyer, H. EMBO J. 1995, 14, 118 7.
25. (f) Johnson, A. T.; Klein, E. S.; Gillett, S. M.; Wang, L.; Song, T. K.; Pino, M. E.; Chandraratna, R. A. S.; J. Med. Chem. 1995, 38, 4764.
26. (g) Teng. M.; Duong, T. T.; Johnson, A. T.; Klein, E. S.; Wang, L.; Khalifa, B.; Chandraratna, R. A. S. J. Med. Chem. 1997, 40, 2445.
27. (h) Tramposch, K. M.; Nair, X.; Marinier, A.; Zusi, C. F. European Patent Appl. WO 9846228, 199 8.
28. (a) Standeven, A. M.; Beard, R. L.; Johnson, A. T.; Boehm, M. F.; Escobar, M.; Heyamn, R. A.; Chandraratna, R. A. S. Fund. Appl. Toxicol. 1996, 33, 264.
29. (b) Kochhar, D. M.; Jiang, H.; Penner, J. D.; Johnson, A. T.; Chandraratna, R. A. S. Int. J. Dev. Biol. 1998, 42, 601.
30. Related tetrahydroanthracenyl retinoids have been described previously as potent RAR agonists, (a) Delescluse, C.; Cavey, M. T.; Martin, B.; Bernard, B. A.; Reichert, U.; Maignan, J.; Darmon, M.; Shroot, B. Mol. Pharmacol. 1991, 40, 556.
31. (a) Shroot, B.; Eustache, J.; Watts, O.; Bernardon, J. M.; Nedoncelle, P. European Patent Application, 210929, 1986.
32. Buckle, D. R.; Arch, J. R. S.; Fenwick, A. E.; Hoge-Frydrych, C. S. V.; Pinto, I. L.; Smith, D. G.; Taylor, S. G.; Tedder, J. J. Med. Chem. 1990, 33, 3028.
33. (a) Christensen, K.; Estes, P. A.; Onate, S. A.; Beck, C. A.; DeMarzo, A. Mol. Endocrinol. 1991, 5, 1755.
34. (b) Cheng, Y. C.; Prussof, W. H. Biochem. Pharm. 1973, 22, 3099.
35. (c) Umesono, K.; Giguere, V.; Glass, C. K.; Rosenfeld, M. G.; Evans, R. M. Nature 1988, 336, 262.
36. (a) Different concentrations of TTNPB were used in the functional antagonism assays for RARα (32 nM), RARβ (10 nM) and RARγ (3.2 nM) in order to obtain high levels of transactivation at each of the receptor subtypes.
37. 9f
38. Standeven, A. M.; Johnson, A. T.; Escobar, M.; Chandraratna, R. A. S. Toxicol. Appl. Pharmacol. 1996, 138, 169.